MTA-Synergistic PRMT5 Inhibitors for Selective Cancer Cytotoxicity

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for Hodgkin Lymphoma and other cancers with wild type MTAP gene but MTA accumulation lack specificity and efficacy, leading to off-target toxicities due to non-selective PRMT5 inhibitors.

Innovation Solution

Administer MTA synergistic PRMT5 inhibitors that selectively target PRMT5 in the presence of MTA, exploiting the 'collateral vulnerability' of tumors with wild type MTAP gene silencing through hypermethylation or downregulation, thereby reducing off-target toxicities.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If non-selective PRMT5 inhibitors are used to treat cancers with MTA accumulation, then anti-proliferative activity is achieved, but off-target toxicities occur due to lack of specificity

Engineering Contradiction:

Improveanti-proliferative activityVSAvoidoff-target toxicities

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies local quality by designing PRMT5 inhibitors with specific molecular structures that only bind to PRMT5 when MTA is present. This creates a localized therapeutic effect specifically in tumor cells with MTA accumulation, while sparing normal cells that do not accumulate MTA, thereby eliminating off-target toxicities while maintaining anti-proliferative activity.

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent uses MTA as an intermediary molecule that mediates the selective binding of PRMT5 inhibitors to PRMT5. MTA acts as a co-synthetizer that enables the inhibitor to recognize and bind to the PRMT5 enzyme only in the presence of high MTA concentrations, providing selective targeting without affecting normal tissues.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If PRMT5 inhibition is applied to tumors with wild type MTAP gene, then treatment efficacy is improved, but selectivity is reduced leading to increased toxicity

Engineering Contradiction:

Improvetreatment efficacyVSAvoidselectivity

Core Design Contradiction:

ReliabilityVSManufacturing precision

Solution Approach 1:

The patent applies parameter changes by modifying the binding affinity and selectivity parameters of the PRMT5 inhibitor based on the MTA concentration level. The inhibitor is designed to have high binding affinity only when MTA is present at elevated concentrations, allowing the system to adapt its selectivity parameter dynamically to the specific tumor type being treated.

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The MTA synergistic PRMT5 inhibitors demonstrate selective cytotoxicity in tumors with wild type MTAP gene silencing, minimizing off-target effects and enhancing treatment efficacy.

Implementation Method 1

MTA-synergistic PRMT5 inhibitors, i.e. PRMT5 inhibitors that bind to PRMT5 preferentially in the presence of MTA

Methodology Applied

Scientific EffectSynergistic binding:

Data Source

PatentUS20260048040A1MTA-cooperative PRMT5 inhibitors for use in the treatment of cancer

Publication Date: 2026.02.19 ASTRAZENECA AB

AI summary

The present specification relates to methods of treatment of wild type MTAP gene cancers comprising administering a MTA synergistic PRMT5 inhibitor to a patient in need thereof.